Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA	Cerebral Small Vessel Diseases, Skin and Connective Tissue Diseases, anti-neutrophil cytoplasmic antibody-associated vasculitis, autoimmune disease, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, granulomatosis with polyangiitis, immune system disorder, interstitial lung disease, lung disorder, microscopic polyangiitis, necrotizing vasculitis, nervous system disorder, respiratory system disorder, skin disorder, skin vascular disease, vascular disorder, vasculitis	Active, not recruiting	Phase 2	2026-09-04		NCT06868290

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Novartis Pharmaceuticals	432

14 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Baylor University Medical Center	Dallas	United States	87
Duke Clinical Research Institute	Durham	United States	3
Houston Methodist Hospital	Houston	United States	260
LDS Hospital	Salt Lake City	United States	82
Massachusetts General Hospital	Boston	United States	1015
Mayo Clinic Jacksonville	Jacksonville	United States	67
Mayo Clinic Rochester	Rochester	United States	133
Michigan Med University of Michigan	Ann Arbor	United States	2
Northwestern University	Chicago	United States	727
Oregon Health Sciences University	Portland	United States	33
Uni of Chi Medi Ctr Hema and Onco	Chicago	United States	5
University of Colorado	Aurora	United States	147
University of Minnesota	Minneapolis	United States	325
University of Pennsylvania	Philadelphia	United States	507